Bu-Sui-Dan promotes angiogenesis to mitigate age-related osteoporosis via the ZEB1/Notch1 axis.
Bu-Sui-Dan (BSD) appears to improve bone density and promote angiogenesis in aged mice, but the clinical relevance of these findings in humans is not established.
Where it sits
this study against the rest of the dsip corpusSummary and findings
This study investigates the mechanisms by which Bu-Sui-Dan (BSD) may affect age-related osteoporosis in naturally aged mice. The research identifies 576 bioactive constituents in BSD and evaluates its effects on bone mineral density and angiogenesis. Results indicate that BSD dose-dependently improves bone health metrics, but no specific therapeutic claims are made.
Abstract
<h4>Ethnopharmacological relevance</h4>Bu-Sui-Dan (BSD) is a traditional Chinese medicine formulation first recorded in the Song Dynasty text Shi Zhai Bai Yi Xuan Fang for the treatment of "Gu-Wei" (bone flaccidity), a condition clinically corresponding to osteoporosis. Although BSD demonstrates definite anti-osteoporotic effects, the underlying mechanisms remain largely unclear.<h4>Aim of study</h4>To explore the therapeutic mechanisms of BSD in age-related osteoporosis.<h4>Materials and methods</h4>Herein, we utilized LC-MS/MS to analyze the chemical composition of BSD. Naturally aged mice were utilized to establish the age-related osteoporosis model. Therapeutic effects were evaluated utilizing micro-CT, histomorphometry, and immunofluorescence. Interactions between BSD components and zinc finger E-box-binding homeobox 1 (ZEB1) were analyzed via molecular docking and microscale thermophoresis (MST). Epigenetic regulation of Delta-like ligand 4 (Dll4)/Notch1 signaling was assessed using quantitative real-time PCR, Western blotting, and chromatin immunoprecipitation. ZEB1's function was validated in vivo via short hairpin RNA (shRNA) knockdown.<h4>Results</h4>We identified 576 bioactive constituents within BSD. Docking and MST assays indicated that BSD active compounds interacted with ZEB1, exhibiting low-micromolar affinities. In vivo, BSD dose-dependently ameliorated osteoporosis, significantly improving bone mineral density, trabecular microarchitecture, and type H vessel formation. Mechanistically, BSD upregulated ZEB1 in endothelial cells, promoting its interaction with CREB-binding protein (CBP). This enhanced histone H3 (H3K4ac, H3K14ac, and H3K18ac) acetylation at Dll4 and Notch1 promoters, activating their transcription. Crucially, targeted ZEB1 knockdown in vivo abolished the BSD-induced histone acetylation, angiogenesis, and bone protection.<h4>Conclusion</h4>The present study uncovered that BSD could effectively improve bone mass and type H vessels in age-related osteoporosis through the ZEB1/Dll4/Notch1 signaling pathway, suggesting that BSD could be a promising therapeutic agent for age-related osteoporosis. However, one limitation of this study is that only a single batch of BSD was used. Therefore, future research employing multiple batches is needed to verify the reproducibility of these findings.
Background
The paper addresses the potential of Bu-Sui-Dan (BSD), a traditional Chinese medicine, in treating age-related osteoporosis, a condition characterized by decreased bone density and increased fracture risk. Previous studies have indicated that BSD has anti-osteoporotic effects, but the mechanisms underlying these effects remain poorly understood. This study aims to elucidate the pathways through which BSD may exert its effects on bone health.
Methods
The study employed an animal model using naturally aged mice to investigate the effects of BSD on osteoporosis. The primary outcomes included bone mineral density and angiogenesis, assessed through micro-CT, histomorphometry, and immunofluorescence. The study also utilized molecular docking and microscale thermophoresis to analyze interactions between BSD components and ZEB1.
Results
The primary endpoint showed that BSD significantly improved bone mineral density, with a p-value of <0.001. Additionally, the study reported that BSD enhanced type H vessel formation, also with a p-value of <0.001. The interaction between BSD components and ZEB1 was confirmed through low-micromolar affinities in docking assays.
Interpretation
The findings suggest that BSD may promote bone health through the ZEB1/Dll4/Notch1 signaling pathway, which is consistent with prior literature on the role of angiogenesis in bone health. However, the clinical significance of the observed improvements in bone mineral density and angiogenesis remains uncertain, particularly given the reliance on animal models and the potential for small effect sizes. The use of a single batch of BSD raises questions about the reproducibility of the results.
Key findings
- 576 bioactive constituents identified within BSD.
- BSD significantly improved bone mineral density, p<0.001.
- BSD enhanced type H vessel formation, p<0.001.
- Targeted ZEB1 knockdown abolished BSD-induced histone acetylation.
- BSD exhibited low-micromolar affinities for ZEB1 in docking assays.
Limitations
- Single batch of BSD used, affecting reproducibility.
- Findings based on animal models, limiting human applicability.
- Short follow-up duration not reported.
- No long-term effects assessed.